Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

medical imaging carbon emissions climate change

PET is an energy hog, but relatively rare utilization lessens its carbon footprint. MRI and CT have no such ‘out’

Medical imaging machinery uses a lot of power, and the extent to which it quickens the pace of global warming is becoming clearer.

May 16, 2024
A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers.

Researchers identify new PET imaging biomarker capable of predicting immunotherapy success

A newly identified PET imaging biomarker could help providers tailor immunotherapy treatments for patients with certain types of cancers. 

May 14, 2024
merger acquisition handshake deal business agreement partnership

Siemens Healthineers inks data sharing deal with Blue Earth to bolster development of prostate cancer AI

Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma.

May 9, 2024
Financial data showing growing revenue

RadNet sees quarterly revenue climb to ‘record’ $432M with double-digit growth across multiple modalities

Comparing only imaging centers that operated both quarters, MRI volumes increased 10% compared to Q1 of 2023 while PET/CT was up more than 15%. 

May 9, 2024
Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration.

New PET agent offers 'exceptional' imaging of kidney cancer

The agent was found to be better than standard CT imaging for patients with clear cell renal cell cancer.

May 8, 2024
Multiple sclerosis ribbon MS

New PET technique spots 'smoldering' changes not visible on MRI in the brains of MS patients

The new technique uncovers hidden inflammation in patients who, despite undergoing extensive treatment for the condition, had worsening symptoms.

April 24, 2024
PET brain scan

Imaging agent that targets deadly brain tumors given FDA's Fast Track designation

Fast Track designations are typically granted to drugs that target an unmet medical need. 

April 17, 2024
scan of prostate

PET/MRI may reduce unnecessary prostate biopsies by 83%

A study out of China found most patients biopsied for prostate lesions did not have clinically significant cancer, calling the clinical ranking systems into question.

April 12, 2024